Clinical Trials Resource Center

Gynecological Infections

August 26, 2002

In an open label study of topical nitroglycerin (NTG) in subjects with vulvodynia, results showed significant decreases in pain intensity and frequency of overall pain. Improvement in pain was reported by 31 of the 34 female subjects. Cellegy Pharmaceuticals, who sponsored the study, plans to develop a topical NTG product for the vulvodynia indication.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.